Brief: Incannex Reports Positive Results From Phase 2 Clinical Trial Of PSX-001 (Psi-GAD) For Generalised Anxiety Disorder
26/08/2025 13:14
Aug 26 (Reuters) - Incannex Healthcare Inc IXHL.O: INCANNEX REPORTS POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF PSX-001 (PSI-GAD) FOR GENERALISED ANXIETY DISORDER INCANNEX HEALTHCARE INC - PSX-001 SHOWS SIGNIFICANT IMPROVEMENTS IN GAD TREATMENT INCANNEX HEALTHCARE INC - PSI-GAD TREATMENT WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS INCANNEX HEALTHCARE: PHASE 2 PSI-GAD TRIAL SHOWS SIGNIFICANT IMPROVEMENTS ACROSS ALL PRIMARY & SECONDARY ENDPOINTS Source text: ID:nGNXbK7lHW Further company coverage: IXHL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsIncannex Healthcare Inc reports results for the quarter ended June 30 - Earnings Summary
Incannex Healthcare Inc expected to post a loss of 75 cents a share - Earnings Preview
Brief: Incannex Receives Additional A$5.1 Million Research And Development Tax Incentive Refund
Brief: Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea
Brief: Incannex Reactivates Share Repurchase Program, Underscoring Confidence In Valuation And Strategic Position